Short Interest in CG Oncology, Inc. (NASDAQ:CGON) Expands By 16.9%

CG Oncology, Inc. (NASDAQ:CGON) saw a large growth in short interest in the month of July. As of July 31st, there was short interest totalling 6,840,000 shares, a growth of 16.9% from the July 15th total of 5,850,000 shares. Based on an average daily trading volume, of 653,700 shares, the days-to-cover ratio is presently 10.5 days. Approximately 16.8% of the company’s shares are short sold.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on CGON shares. The Goldman Sachs Group upgraded shares of CG Oncology from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $43.00 to $50.00 in a report on Monday, May 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $75.00 price objective on shares of CG Oncology in a research report on Thursday, May 2nd. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price objective on shares of CG Oncology in a research note on Tuesday, May 28th. Finally, Bank of America initiated coverage on CG Oncology in a research note on Friday, June 28th. They issued a “buy” rating and a $65.00 target price for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, CG Oncology currently has a consensus rating of “Buy” and an average price target of $64.00.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. acquired a new stake in shares of CG Oncology in the 1st quarter valued at approximately $102,000. California State Teachers Retirement System acquired a new stake in CG Oncology in the first quarter valued at $103,000. Profund Advisors LLC bought a new position in shares of CG Oncology in the 2nd quarter valued at about $300,000. BNP Paribas Financial Markets acquired a new position in shares of CG Oncology during the 1st quarter worth about $492,000. Finally, Capstone Investment Advisors LLC bought a new stake in shares of CG Oncology in the 1st quarter valued at about $806,000. 26.56% of the stock is owned by institutional investors and hedge funds.

CG Oncology Trading Down 0.5 %

CGON traded down $0.18 during trading on Friday, hitting $34.22. The company had a trading volume of 468,517 shares, compared to its average volume of 647,165. CG Oncology has a one year low of $25.77 and a one year high of $50.23. The firm’s 50-day moving average price is $33.28 and its 200 day moving average price is $36.38.

CG Oncology (NASDAQ:CGON) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.14. The firm had revenue of $0.11 million during the quarter. As a group, research analysts anticipate that CG Oncology will post -1.64 EPS for the current fiscal year.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.